765297-57-2

Upstream product

• 100-39-0 benzyl bromide 
• 261165-05-3 (1S,3R)-3-(tert-butoxycarbonylamino)cyclopentanecarboxylic acid 
• 693245-54-4 (1S,3R)-benzyl-(N-BOC-3-amino)-cyclopentanecarboxylate 
• 625098-77-3 C₁₃H₁₇NO₂ 
• 151907-80-1 (1R,4S)-4-[(tert-butoxycarbonyl)amino]cyclopent-2-ene-1-carboxylic acid 
• 134003-04-6 (1R,4S)-4-aminocyclopenten-2-ene-1-carboxylic acid 

Downstream Products

• 625098-78-4 benzyl (1S,3R)-3-[(diphenylmethylene)amino]cyclopentanecarboxylate 
• 625098-81-9 C₂₁H₃₁NO₃ 
• 625098-82-0 C₂₃H₃₀F₃NO₄ 
• 625128-83-8 C₂₁H₃₁NO₄ 
• 625126-75-2 benzyl (1S,3R)-3-amino-1-isopropylcyclopentanecarboxylate hydrochloride 

Relevant academic research and scientific papers

AMINOCYCLOPENTYL PYRIDOPYRAZINONE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I and Formula II (wherein A, E, j, k, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

TETRAHYDROPYRANYL CYCLOPENTYL 1-SUBSTITUTED AND 1,1-DISUBSTITUTED TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I: I (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

AMINOCYCLOPENTYL FUSED HETEROTRICYLICAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of formulae (I and II) (wherein A, D, E. X, l, m, n and R through R are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modul

TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.